Honigman Serves as IP Counsel for Kardigan in Closing of $460M Upsized Initial Public Offering

Honigman recently served as IP counsel for Kardigan, Inc. (Nasdaq: KARD), a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, in connection with the closing of its initial public offering. The gross proceeds from the offering were $460 million before deducting underwriting discounts and commissions and other offering expenses. The shares commenced trading on the Nasdaq Global Market on June 18, 2026.

Kardigan was advised by a Honigman IP team that included Partners Andrew Weber, Vikram Mathrani, N. Danny Shulman, Thomas Appledorn, Jonathan O'Brien, Ph.D., Heidi Berven, Ph.D., Christopher DeLucenay, and Li Gao, Ph.D.; Senior Attorney Deborah Martin, Ph.D.; and Of Counsel Jarred Pickering, Ph.D. Each member of the team played an integral role in the matter.